|
Clinical and financial burden of mental health (MH) conditions in patients (pts) with low-grade non-Hodgkin lymphoma (LG-NHL). |
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
Employment - Real Chemistry |
|
|
No Relationships to Disclose |
|
|
Employment - Real Chemistry |
Stock and Other Ownership Interests - Real Chemistry |
|
Asher Alban Akmal Chanan-Khan |
Leadership - Cellectar; STARTON Therapeutics |
Stock and Other Ownership Interests - Cellectar; Matthew & Asher Inc.; NanoDev Therapeutics; STARTON Therapeutics |
Honoraria - Ascentage Pharma; BeiGene |
Consulting or Advisory Role - Ascentage Pharma Group |
Research Funding - Ascentage Pharma |
Patents, Royalties, Other Intellectual Property - Patent on PSMB9 biomarker; Tabi Vaccine |